by
Thomas Dworetzky, Contributing Reporter | December 04, 2017
The deal
surfaced in late October, at which time it was valued at roughly $66 billion.
“I think this deal has been a long time coming,” Adam J. Fein, president of Pembroke Consulting, told the New York Times at the time, noting that, “CVS has been positioning itself as a health care company and not a pharmacy for a long time.”
The move comes after a search for deals across many sectors of health care by the retail drug chain in an effort to squeeze profits out of combinations of varied businesses in the fast-changing health care landscape.
CVS had also reached out to Anthem about a sale, and UnitedHealth Group as well, unnamed sources
told the Wall Street Journal.
At that time,
noted Bloomberg, Amazon was reported to have gotten pharmacy-wholesaler licenses in a dozen states. “Size and scale-wise, they can disrupt anywhere they want to disrupt,” noted Chip Davis, president of the Association for Accessible Medicines.
Back to HCB News
